A lpha-thalassemia X-linked intellectual disability (ATR-X) syndrome (Online Mendelian Inheritance in Man (OMIM) entry 301040) is caused by ATRX mutations [1] [2] [3] . ATRX encodes the switch/sucrose nonfermentable (SWI/SNF)-like chromatin remodeling protein ATRX, which contains two signature motifs. One is a plant homeodomain designated the ATRX-DNMT3-DNMT3L domain, which binds to histone H3 tails, specifically at H3K4me0K9me2/3 (refs [4] [5] [6] ). The other includes seven helicase subdomains that confer ATPase activity 7, 8 . Genome-wide analysis that combines chromatin immunoprecipitation with next-generation sequencing (ChIP-seq) in both primary human erythroid cells and mouse embryonic stem cells (ESCs) shows ATRX enrichment at G-rich variable number tandem repeats, some of which form non-B DNA structures, including G-quadruplexes 9 . ATRX functions as a part of a histone chaperone complex that deposits the histone variant H3.3 onto pericentromeric heterochromatin and telomeres collaborating with death domainassociated protein (DAXX) in HeLa cells 10 and murine ESCs 11, 12 . ATRX/H3.3 co-localization also occurs on the DNA-methylated allele of many imprinted genes and is associated with differentially methylated regions in mouse ESCs
. ATRX functions as a part of a histone chaperone complex that deposits the histone variant H3.3 onto pericentromeric heterochromatin and telomeres collaborating with death domainassociated protein (DAXX) in HeLa cells 10 and murine ESCs 11, 12 . ATRX/H3.3 co-localization also occurs on the DNA-methylated allele of many imprinted genes and is associated with differentially methylated regions in mouse ESCs 13 . Some imprinted genes show upregulated expression in the forebrain of Atrx conditional knockout (cKO) mice 14, 15 , suggesting that ATRX silences the active allele. Moreover, expression of the autism-related gene Nlgn4 significantly decreases in the forebrain of Atrx cKO mice 16 . Imprinting loss in neurons leads to various mental retardation syndromes, including Prader-Willi and Angelman syndromes 17 . However, the relationship between abnormal expression and cognitive dysfunction in ATR-X syndrome remains unclear.
Results

ATRX regulates
Xlr3b expression in the mouse brain. Atrx ΔE2 mice, which are engineered to lack Atrx exon 2, show cognitive defects, among other phenotypes 18 , and express a mutant protein that corresponds to a variant with an Arg37Stop (R37X) mutation in exon 2 seen in human ATR-X syndrome [19] [20] [21] . Moreover, Atrx ΔE2 mice show 80% reduction in ATRX protein levels 18, 19 , similar to outcomes seen in 27 individuals with ATR-X syndrome 8 . We used DNA microarrays to assess the transcriptional profiles at post-natal day 90 (P90) in the hippocampus of wild-type (WT) and Atrx ΔE2 mice. To identify differentially expressed genes, we used an algorithm combining the false discovery rate (FDR) and fold change in expression and identified 31 genes (8 upregulated and 23 downregulated) in WT versus Atrx ΔE2 samples. Among them was Atrx itself, which was downregulated in Atrx ΔE2 mice (see Supplementary Table 1 for a list of genes with an FDR < 0.05 and a log 2 fold change of > 0.5 or < − 0.5). Among the genes that were markedly upregulated in Atrx ΔE2 mice was a member of the lymphocyte-regulated (Xlr) gene family, Xlr3a, and the imprinted gene Xlr3b [22] [23] [24] (FDR < 0.05 and log 2 fold change > 0.5; Fig. 1a ). Xlr3a and Xlr3b genes show 94% protein similarity, and DNA microarrays are limited in their ability to distinguish related factors. Thus, we carried out reverse transcription PCR (RT-PCR) analysis with a common forward (FW) primer and subtype-specific reverse (RV) primers ( Supplementary Fig. 1a ).
Targeting G-quadruplex DNA as cognitive function therapy for ATR-X syndrome
titative RT-PCR (RT-qPCR) indicated Xlr3b transcript upregulation in some brain areas, including the hippocampus, of Atrx ΔE2 mice, but not in peripheral tissues (Fig. 1b) .
Next, to investigate changes in Xlr3 protein expression, we generated an Xlr3 antibody. To confirm its specificity, we performed Xlr3-KO validation using clustered regularly interspaced Table 1 (which contains a list of genes with an FDR < 0.05 and a log 2 fold change of > 0.5 or < − 0.5). n = 7 mice each. b, Real-time RT-qPCR showing Xlr3b mRNA expression in mouse lysates. **P < 0.01 and *P < 0.05 by two-way ANOVA with Bonferroni's post-hoc test; n = 8-12 mice at P90. Medial prefrontal cortex (PC; n = 8 each), hippocampus (HP; n = 10 each), hypothalamus (HT; WT, n = 10; Atrx ΔE2 , n = 8), cerebellum (CE; WT, n = 9; Atrx ΔE2 , n = 10) and the lung, liver, heart and kidney (n = 12 each). c, Representative immunoblot of P90 mouse brain lysates probed with the indicated antibodies (top panel). Densitometric analysis of Xlr3 normalized to β -tubulin (arbitrary units (AU)) (bottom panel). **P < 0.01, *P < 0.05 by two-way ANOVA with Bonferroni's post-hoc test; n = 4 mice each. d, The percentage of 5-methylcytosine (5-mC) as determined by bisulfite sequencing analysis in the whole brain from male P90 WT or Atrx ΔE2 mice. **P < 0.01 by two-sided, unpaired t-test. n = 12 clones each. (n = 3 mice each and 4 clones were sequenced per mouse.) See also Supplementary Fig. 2 . e, Xlr3b-ODN showing intramolecular parallel G-quadruplexes, which formed three separate G-quartets stacked 5′ to 3′ with three loops. The underlined guanines indicate dimethyl sulfate (DMS)-unreactive guanines. See also Supplementary Fig. 3 . f,g, Luciferase activity of Neuro-2a cells co-transfected with plasmids identified in the left margin plus other indicated plasmids. Luciferase activity is presented relative to its activity in mock cells. **P < 0.01 by one-way ANOVA with Bonferroni's post-hoc test; n = 6 biologically independent samples. G4, G-quadruplex. h, Schematic of Xlr3b: G-quadruplex-forming sequence (yellow), CGI (gray) and R1 and R2 regions (top panel). Analysis of R1 and R2 regions in chromatin from the hippocampus of Atrx ΔE2 and WT mice by ChIP with the indicated antibodies (bottom panel). Results are expressed as the percent input. **P < 0.01, *P < 0.05 by two-sided, unpaired t-test. n = 6 mice at P90. IP, immunoprecipitation. In panels b-d,f-h, the means ± s.e.m. are shown. Full-size scans of western blots are shown in Supplementary Fig. 13 .
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NATuRe MeDICINe short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) in cultured hippocampal neurons. To do so, we transduced cultured hippocampal neurons with lentivirus harboring U6gRNA-Cas9-2A-GFP plus guide Xlr3 single-guide RNA (sgRNA; Xlr3-Cas9-GFP) or control lentivirus expressing green fluorescent protein (GFP). Microscopy analysis revealed loss of Xlr3 immunoreactivity in microtubule-associated protein 2 (MAP2)-positive neurons infected with Xlr3-Cas9-GFP but not the control GFP virus (Supplementary Fig. 1d ). We also confirmed Xlr3b-KO efficacy by RT-qPCR in cultured hippocampal neurons (Supplementary Fig.  1e ). Western blot analysis with the Xlr3 antibody also showed significantly decreased protein expression in KO relative to WT cultured hippocampal neurons ( Supplementary Fig. 1f ), confirming antibody specificity. Next, we used the Xlr3 antibody to examine Xlr3 protein expression in the Atrx ΔE2 mouse prefrontal cortical, hippocampal, hypothalamic and cerebellar tissues by western blot and observed significant increases in Xlr3 protein levels in the brain of Atrx ΔE2 relative to WT mice (Fig. 1c) . CpG island (CGI) methylation by DNA methyltransferases (DMNTs) generally represses transcription 25 , and cKO mice lacking Dnmt1 or both Dnmt1 and Dnmt3a in forebrain neurons show increased Xlr3b expression 26, 27 . Although ATRX lacks a canonical DNMT motif, human ATRX mutations are associated with altered DNA methylation patterns at various genomic loci 28 . Moreover, the Xlr3 gene CGIs display similar sequences, and a sequence potentially forming a G-quadruplex structure is specific to Xlr3b (Supplementary Fig. 2a ). Thus, we asked whether ATRX recruits DNMTs to methylate Xlr3b CGIs. To do so, we used bisulfite sequencing to compare DNA methylation levels in Xlr3b CGIs of whole-brain samples from WT or Atrx ΔE2 mice. Relative to WT mice, Atrx ΔE2 mice showed significantly decreased levels of DNA methylation at Xlr3b CGIs, whereas we observed no difference in DNA methylation levels in the CGIs of other Xlr3 subfamily genes between genotypes ( Fig. 1d and Supplementary Fig. 2b ). Circular dichroism (CD) spectra of a synthetic oligodeoxynucleotide containing sequences that potential form a G-quadruplex in Xlr3b CGIs (Xlr3b-ODN) showed a spectrum characteristic of parallel G-quadruplexes in 10 and 100 mM KCl, with maximum absorbance at 265 nm and minimum at 240 nm ( Supplementary Fig. 3a ). This conformational change in physiological conditions (100 mM KCl) was reflected by decreased DNA mobility in gel shift assays performed using native polyacrylamide gel electrophoresis (PAGE) gels ( Supplementary Fig. 3b ). We then undertook dimethyl sulfate (DMS) footprinting of Xlr3b-ODN to assess the formation of an intramolecular parallel G-quadruplex consisting of a core of three stacked G-quartets and three loops ( Fig. 1e and Supplementary Fig. 3c ). This analysis confirmed that Xlr3b CGI sequences can form parallel G-quadruplex structures.
To assess how ATRX regulates Xlr3b, we performed luciferase reporter assays. To do so, we first cloned three different Xlr3b genomic sequences into a pGL3 luciferase reporter vector. They included: a 2.0-kb fragment (designated pGL3-2K) upstream of the Xlr3b ATG initiation codon; a pGL3-2K deletion mutant lacking G-quadruplex-forming sequences (pGL3-2KΔ G4); and a 1-kb Xlr3b upstream sequence (pGL3-1KΔ CGI) that lacks CGIs. Mouse neuroblastoma Neuro-2a cells transfected with pGL3-2K showed significantly reduced luciferase activity when co-transfected with ATRX; conversely, luciferase activity relative to controls increased in cells co-transfected with ATRX shRNA (Fig. 1f) . However, cells transfected with either pGL3-2KΔ G4 or pGL3-1KΔ CGI showed activity comparable to cells co-transfected with ATRX or ATRX shRNA, suggesting that ATRX regulates Xlr3b through the G-quadruplex structure (Fig. 1f) . We confirmed ATRX shRNA knockdown efficacy by immunoblotting for endogenous ATRX protein in Neuro-2a cells (Supplementary Fig 4a) . Moreover, Neuro-2a cells co-transfected with pGL3-2K plus DNMTs (DNMT1 or DNMT3A) showed significantly decreased reporter activity relative to respective controls (Fig. 1g) . However, cells co-transfected with pGL3-2K plus DAXX or H3.3 showed comparable reporter activity. Importantly, cells co-transfected with pGL3-2KΔ G4 plus DNMTs showed no change in reporter activity relative to pGL3-2KΔ G4 alone. Finally, we methylated pGL3-2K, pGL3-2KΔ G4 and pGL3-1KΔ CGI constructs using CpG DNMT M.SssI and assessed the luciferase activity. We observed decreased luciferase activity in methylated pGL3-2K and pGL3-2KΔ G4, but not in methylated pGL3-1KΔ CGI, supporting the idea that CGI methylation inhibits Xlr3b expression (Fig. 1g) .
To determine whether ATRX and interacting factors target Xlr3b CGIs in the mouse hippocampus, we performed ChIP-qPCR with an ATRX antibody. We confirmed that hippocampal samples from Atrx ΔE2 mice contained detectable levels of ATRX protein: those lysates showed an 80% reduction in ATRX protein levels relative to lysates from WT mice, and the ATRX antibody recognized both WT and mutant ATRX protein as described in refs 18, 19 ( Supplementary Fig 4b) . Co-immunoprecipitation in hippocampal lysates revealed that ATRX interacts with DNMT1, DNMT3A, DAXX and H3.3 from both WT and Atrx ΔE2 mice, and relatively low amounts of DNMT1, DNMT3A, H3.3 and DAXX were detected in immunoprecipitated samples of Atrx ΔE2 mice ( Supplementary  Fig 4c) . We detected substantial ATRX enrichment at Xlr3b CGIs containing G-quadruplexes based on ChIP analysis with primers targeting the Xlr3b region R1 in chromatin isolated from the WT mouse hippocampus, whereas ATRX interaction with chromatin at this site was greatly decreased in the Atrx ΔE2 hippocampus (Fig. 1h ). The levels of DNMT1, DNMT3A, DAXX and H3.3 were also significantly decreased in Atrx ΔE2 relative to WT chromatin in the R1 region. Furthermore, quantitative profiling of ATRX, DNMTs, DAXX and H3.3 across an unrelated R2 region revealed small peaks, demonstrating enrichment of these proteins at Xlr3b CGIs (Fig. 1h) . Overall, these observations suggest that ATRX binds to parallel G-quadruplexes in Xlr3b CGIs along with DNMTs, DAXX and H3.3, where it regulates Xlr3b gene expression.
Neuronal RNA granules contain Xlr3b. We next undertook a proteomic screen to search for Xlr3 interaction partners by performing liquid chromatography-tandem mass spectrometry (LC-MS/MS) of proteins pulled down from lysates of P60 WT mouse brain with an Xlr3 antibody. LC-MS/MS analysis revealed an endogenous Xlr3 complex containing multiple components, including actin/myosin-related proteins, dynein motor complex (DYNLL, DYNLRB, DYNLT and DYNC1LI2) proteins, ribonucleoproteins (hnRNP A/B and hnRNP D) and 40S ribosomal proteins (RPS10 and RPS25), among others ( Fig. 2a and Supplementary Table 2 ). We then confirmed the association of purified GST-Xlr3b protein with hnRNP A/B, hnRNP D, DYNLL and DYNC1LI2 by in vitro pulldown assays in mouse hippocampal lysates (Fig. 2b) . Purified Xlr3b protein did not bind to F-actin and its presence did not alter actin polymerization ( Supplementary Fig. 5a,b) . To confirm interactions in vivo, we performed immunoprecipitation of mouse hippocampal extracts with an Xlr3 antibody followed by immunoblotting with hnRNP A/B, hnRNP D, DYNLL or DYNC1LI2 antibodies and observed coprecipitation of all with Xlr3 (Fig. 2c) .
To determine Xlr3 cellular localization, we undertook immunofluorescence of mature MAP2-positive cultured neurons with an Xlr3 antibody. Xlr3 was localized to nuclei and perinuclear areas and was seen in granules in MAP2-positive dendrites and synaptic synaptophysin-positive puncta (Fig. 2d) . Xlr3-positive structures of this type were also observed in MAP2-positive dendrites in mouse hippocampal CA1 analyzed at P60 (Fig. 2e) . In dendrites, Xlr3-positive puncta co-localized with hnRNP A/B and cytotoxic granuleassociated RNA-binding protein 1 (TIA1), which are both found in RNA granules 29 , and with SYTO 14-visualized RNA. Xlr3-positive 
NATuRe MeDICINe granules did not co-localize with DCP1a, a marker of RNAprocessing bodies 29 ( Fig. 2f ). Xlr3b exhibits a predicted nuclear localization signal (NLS) at amino acid residues 2-11; residues 74-200 also constitute a conserved Cor1/Xlr/Xmr region (Cor1 domain). To assess the function of those sequences, we transfected Neuro-2a cells with FLAGtagged Xlr3b or similarly tagged deletion mutants shown in Fig.  2g and analyzed their location by confocal microscopy (Fig. 2g) . Based on FLAG expression, full-length Xlr3b (FL-Xlr3b) significantly co-localized with TIA1 in nuclear regions compared to nontransfected cells. FL-Xlr3b also accumulated with hnRNP A/B in nuclei, but not with DCP1a ( Fig. 2g and Supplementary Fig. 6a,b) . Cells transfected with constructs lacking amino acid residues 2-11 (Δ NLS) or 74-123 (Δ 74-123) showed partial loss of Xlr3b nuclear localization, but localization of the interacting proteins TIA1 and hnRNP A/B was unchanged. These localization patterns were similar to those seen in FL-Xlr3b-transfected cells ( Fig. 2g and Supplementary Fig. 6a To confirm interactions of Xlr3b amino acid residues 158-170 with RNA-binding proteins (RBPs), we used Xlr3b inhibitory peptide (XIP), a 29-amino acid peptide containing Xlr3b amino acid residues 158-170 plus the cell-permeable antennapedia homeodomain (ANTP) peptide ( Supplementary Fig. 7a ). When FL-Xlr3b-transfected cells were treated with XIP (1 μ M for 4 h), TIA1 did not accumulate in the nucleus ( Supplementary Fig. 7b ). We confirmed that XIP, but not the ANTP control peptide, bound to RBPs, TIA1 and hnRNP A/B using pulldown assays of mouse hippocampal lysates with an ANTP antibody (Supplementary Fig. 6d ).
Phylogenetic analysis identified the FAM9 gene family as human Xlr orthologues, and FAM9 proteins are predicted to have a Cor1 domain 31 . BLAST (Basic Local Alignment Search Tool) searches indicated that Xlr3b residues 158-170 are highly conserved in Cor1 domains of FAM9 family proteins, including FAM9A and FAM9B ( Supplementary Fig. 6e ). We observed nuclear localization of FLAGtagged FAM9A overexpressed in Neuro-2a cells, whereas a similar construct lacking residues analogous to Xlr3b 158-170 was found in cytoplasmic inclusion body-like structures in a pattern similar to Xlr3b Δ 158-170-transfected cells ( Supplementary Fig. 6e ).
Aberrant Xlr3b expression in neurons decreases synaptic plasticity by inhibiting the transport of dendritic Camk2a mRNA. In neurons, RNA granules are rapidly transported to dendrites, a process regulated by motor proteins 32 . Some RBPs, including hnRNP A/B, recognize a specific cis-acting element termed the hnRNP A2 response element (A2RE) in mRNA 3′ untranslated regions (3′ UTRs); these include Ca 2+ /calmodulin-dependent protein kinase II-α (CaMKII-α ; encoded by Camk2a), activity-regulated cytoskeleton-associated protein (Arc) and brain-derived neurotrophic factor (BDNF) 33 . Because Xlr3b interacts with the dynein motor complex and RBPs, we hypothesized that Xlr3b regulates dendritic mRNA transport via a dynein-mediated transport mechanism.
To test this hypothesis, we undertook RNA immunoprecipitation in mouse hippocampal lysates to determine whether an endogenous Xlr3 complex associates with dendritic mRNAs. After immunoprecipitation with an Xlr3 antibody, we isolated total RNA from precipitates and analyzed it by qPCR with primers specific to the 3′ UTRs of the mRNAs encoding CaMKII-α , Arc and BDNF. Immunoprecipitates contained all three mRNAs, and XIP treatment (1 μ M for 2 h) of cell lysates significantly blocked these interactions (Fig. 3a) .
Atrx ΔE2 mice show cognitive impairment and CaMKII-α dysfunction 18, 19 . Thus, we focused on dendritic Camk2a mRNA. To determine whether Xlr3b protein is co-transported into dendrites with Camk2a mRNA, we used dual-color time-lapse imaging with mCherry-Xlr3b and GFP-MS2-labeled Camk2a mRNA (GFPCaMKII-α 3′ UTR) 34 . mCherry-Xlr3b co-localized with the GFPCaMKII-α 3′ UTR and both were co-transported to dendrites of cultured neurons (Fig. 3b) . By contrast, co-localization of mCherryXlr3b mutants (∆ 124-200 and Δ 158-170) with GFP-CaMKII-α 3′ UTR immunofluorescence was rarely seen ( Supplementary Fig. 8a ). To analyze the dynamics of dendritic Camk2a mRNA transport, we investigated the movement of the GFP-CaMKII-α 3′ UTR in proximal dendrites (20-100 μ m away from the cell body). Granules moved in anterograde and retrograde directions (Fig. 3c , top left panel). Figure 3c (top right panel) shows a representative kymograph corresponding to 15 min of live imaging of GFP-CaMKII-α 3′ UTR movement in a proximal dendrite (also see Supplementary Video 1). Imaging of GFP-CaMKII-α 3′ UTR movement revealed that approximately half of the observed Camk2a mRNA granules were immobile, and the few mobile granules showed bidirectional movement in cultured WT neurons. The number of bidirectionally mobile Camk2a mRNA granules significantly decreased in cultured neurons of transgenic mice overexpressing Xlr3b driven by the neuron-specific Thy1.2 promoter (Thy1-Xlr3b TG mice; Supplementary  Fig. 9a-d) , relative to the effects seen in WT neurons. Moreover, in cultured neurons of Atrx ΔE2 mice, the number of bidirectionally mobile Camk2a mRNA granules significantly decreased. Xlr3b-shRNA transfection or XIP treatment antagonized the decreases in dendritic Camk2a mRNA transport seen in Atrx ΔE2 neurons, suggesting that Xlr3b, acting through RBPs, inhibits Camk2a mRNA transport (Fig. 3c, bottom) . We confirmed the efficacy of Xlr3b knockdown by immunoblotting of endogenous Xlr3 protein in cultured neurons (Supplementary Fig. 9e ). In addition, the dynamics of Camk2a mRNA transport in distal dendrites (100-200 μ m from the cell body) were similar to that seen in proximal dendrites: the number of bidirectionally mobile Camk2a mRNA granules significantly decreased in Thy1-Xlr3b TG and Atrx ΔE2 neurons relative to the effects seen in WT neurons. Furthermore, Xlr3b-shRNA transfection or XIP treatment rescued the decreases in dendritic Camk2a mRNA transport seen in Atrx ΔE2 neurons ( Supplementary Fig. 8b and Supplementary Video 2).
RNA granules localize beneath postsynaptic sites in dendrites, and Camk2a mRNA is located in dendrites and active postsynaptic regions 33 . Indeed, the number of double-positive protein puncta containing the GFP-CaMKII-α 3′ UTR and the postsynaptic marker Articles NATuRe MeDICINe PSD95 significantly decreased in cultured neurons of Thy1-Xlr3b TG and Atrx ΔE2 mice relative to the number seen in WT mice, and cultured neurons from Atrx ΔE2 mice transfected with Xlr3b shRNA or treated with XIP showed a significant increase in the number of double-positive puncta (Fig. 3d) . Next, we performed western blot analysis for CaMKII-α protein in synaptosomal membrane fractions, containing PSD95 isolated from cultured hippocampal neurons ( Supplementary Fig. 9f ). CaMKII-α protein levels were decreased in the synaptosomal membrane fractions from cultured neurons of Thy1-Xlr3b TG and Atrx ΔE2 mice relative to that seen in WT mice. XIP treatment in Atrx ΔE2 neurons significantly increased the synaptosomal CaMKII-α protein levels without changes in both CaMKII-α and PSD95 levels in total cell lysate fractions between groups ( Supplementary Fig. 9f ). 
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Dendritic Camk2a mRNA translation is regulated by synaptic activity, and postsynaptic CaMKII-α protein regulates hippocampal long-term potentiation (LTP), which is critical for learning and memory [35] [36] [37] [38] . To assess a potential effect on LTP, we undertook electrophysiological analysis of brain slices from hippocampal CA1. Consistent with our previous study 19 , we observed markedly reduced high-frequency stimulation (HFS)-induced LTP in Atrx ΔE2 mice, which was significantly rescued by a 2-h bath application of XIP to Atrx ΔE2 mouse samples, but not following application of an ANTP control peptide, suggesting that impaired LTP seen in Atrx ΔE2 mice is in part Xlr3b dependent (Fig. 3e) . Notably, Thy1-Xlr3b TG mice also showed impaired hippocampal LTP (Supplementary Fig. 9g ). We observed no significant difference in basic electrophysiological properties, among them input-output relations and paired-pulse ratio, between groups ( Supplementary  Fig. 9h ). LTP induction, which strengthens synapses, results in CaMKII phosphorylation throughout the dendritic area, suggesting widespread CaMKII activation including in spines 39, 40 . In WT mice, the levels of CaMKII-α phosphorylation significantly increased following hippocampal LTP induction. Consistent with LTP impairment, CaMKII-α phosphorylation levels did not increase following LTP induction in the hippocampus of Atrx ΔE2 and Thy1-Xlr3b TG mice. Notably, bath application of XIP, but not ANTP, significantly restored LTP-induced CaMKII-α phosphorylation in the Atrx ΔE2 hippocampus ( Supplementary Fig. 9i ).
To assess whether Xlr3b overexpression affects cognitive function, we used a novel object recognition task. In training trials, we observed no differences in the discrimination index using the same object between WT and Thy1-Xlr3b TG mice (data not shown). After a 24-h retention interval between trial and test sessions, Thy1-Xlr3b TG mice showed a significantly lower discrimination index for a novel object than did WT mice ( Supplementary Fig. 9j ). To assess contextual memory, we undertook a fear-conditioned passive avoidance task and observed no significant differences in latency to enter a dark room in the absence of a foot shock between WT and Thy1-Xlr3b TG mice (data not shown). However, latency to enter the dark compartment was markedly decreased 1 week after foot shock in Thy1-Xlr3b relative to WT mice ( Supplementary Fig. 9k ). We then used a Y-maze to test spatial working memory and observed that Thy1-Xlr3b mice showed impairment based on the percentage of alternation behaviors relative to WT mice without a change in the total number of arm entries (Supplementary Fig. 9l ).
5-ALA treatment reduces RNA polymerase II recruitment and represses Xlr3b transcription by modifying G-quadruplex structure. G-quadruplex-binding small molecules such as porphyrin function as transcriptional repressors 41 . Thus, we asked whether Xlr3b repression via porphyrin binding to its G-quadruplex structure would antagonize the synaptic dysfunction and cognitive deficits seen in Atrx ΔE2 mice. To do so, we first assessed the intracellular generation of porphyrins following the administration of 5-aminolevulinic acid (5-ALA), which can be metabolized to porphyrins, protoporphyrin IX (PpIX) and hemin 42 (Fig. 4a) . We confirmed PpIX and hemin binding to Xlr3b-ODN G-quadruplexes using UV melting analysis. The difference in melting temperature (Δ T m ) for PpIX and hemin was 2.0 and 2.3 °C, respectively, indicating that PpIX and hemin both moderately bind to the Xlr3b G-quadruplex structure. The Δ T m for TMPyP4, a well-known G-quadruplexbinding ligand, was higher than 4 °C (Supplementary Fig. 10a ). To determine whether 5-ALA treatment alters Xlr3b gene expression, we transfected Neuro-2a cells with the pGL3-2K reporter, treated cells with varying concentrations of 5-ALA or TMPyP4 and assessed the effects of Xlr3b expression based on luciferase assays. As expected, treatment with 5-ALA or TMPyP4 reduced luciferase activity in a dose-dependent manner but had no effect on cells transfected with pGL3-2KΔ G4 (Fig. 4b and Supplementary Fig. 10b ).
Decreased luciferase activity in 5-ALA-treated cells was efficiently rescued by co-treatment with the 5-ALA dehydratase inhibitor succinylacetone (Fig. 4c) . Next, we asked whether treatment with G-quadruplex ligands would inhibit the aberrant Xlr3b gene expression seen in the Atrx ΔE2 mouse brain. To do so, we administered 5-ALA (oral (p.o.), daily from P30 to P90) or TMPyP4 (intraperitoneal (i.p.), twice weekly from P30 to P90). Either treatment significantly blocked the increases in hippocampal Xlr3b mRNA and Xlr3 protein levels seen in vehicle-treated Atrx ΔE2 mice (Fig. 4d ,e and Supplementary Fig. 10c,d) .
To investigate the mechanisms underlying these effects, we undertook bisulfite sequencing to compare DNA methylation levels. Xlr3b CGIs in the hippocampus and prefrontal cortex of Atrx ΔE2 mice showed significantly decreased DNA methylation levels relative to WT mice, an effect that was unchanged by 5-ALA treatment ( Fig. 4f and Supplementary Fig. 10e ). Next, we performed ChIPqPCR of ATRX and RNA polymerase II (Pol II) within the Xlr3b gene, as G-quadruplex structures hinder Pol II passage 43, 44 . The prediction of quadruplex structures within the Xlr3b gene was supported by the G-quadruplex analysis tool QGRS Mapper 45 ( Fig. 4g,  top) . In the WT mouse hippocampus, ATRX and Pol II accumulated at Xlr3b CGIs containing G-quadruplexes, based on analysis using primers targeting amplicon 1, but little signal was seen at amplicons 2, 3 and 4 ( Fig. 4g, bottom) . However, in the Atrx ΔE2 mouse, we detected elevated Pol II signals across all amplicons in the Xlr3b gene body as well as CGIs, indicating enhanced Xlr3b transcription. Furthermore, elevated Pol II signals were significantly attenuated following 5-ALA treatment (Fig. 4g, bottom) . These results suggest that the porphyrin metabolites PpIX and hemin, which are derived from 5-ALA, bind to Xlr3b G-quadruplex structures, partially reducing Pol II recruitment.
Treatment with G-quadruplex ligands counteracts cognitive deficits seen in Atrx
ΔE2 mice. Next, we asked whether 5-ALA treatment rescued the decreases in dendritic Camk2a mRNA transport seen in Atrx ΔE2 neurons. Imaging of GFP-CaMKII-α 3′ UTR movement revealed that the decreased number of bidirectionally mobile Camk2a mRNA granules was significantly rescued in 5-ALAtreated Atrx ΔE2 neurons (7 days, 1 μ M) at proximal and distal dendrites ( Fig. 5a and Supplementary Fig. 11a ). The decreased number of double-positive protein puncta containing GFP-CaMKII-α 3′ UTR and PSD95 in Atrx ΔE2 neurons was also significantly rescued (Fig. 5b) . Moreover, reduced HFS-induced LTP in the hippocampus of vehicle-treated Atrx ΔE2 mice was significantly restored in 5-ALAtreated Atrx ΔE2 mice (p.o. daily from P30 to P90) without a change in basic electrophysiological properties ( Fig. 5c and Supplementary  Fig. 11b ). Finally, 5-ALA treatment significantly blocked the decreased CaMKII-α protein level at synaptosomal membrane fractions in cultured hippocampal neurons from Atrx ΔE2 mice and restored LTP-induced CaMKII-α phosphorylation in the hippocampus of Atrx ΔE2 mice (Supplementary Fig. 11c ). We next administered 5-ALA (p.o. daily from P30 to P90) or TMPyP4 (i.p. twice weekly from P30 to P90) to Atrx ΔE2 mice and subsequently assessed memory-related behaviors. We observed no differences in the discrimination index in a novel object recognition task using the same object in all groups in training trials (data not shown). After a 24-h retention interval between trial and test sessions, Atrx ΔE2 mice showed a significantly lower discrimination index for a novel object than did WT mice. The discrimination index for the novel object in Atrx ΔE2 mice treated with 5-ALA or TMPyP4 was significantly higher than that seen in vehicle-treated groups ( Fig. 5d and Supplementary Fig. 11d ). In a fear-conditioned passive avoidance task, we observed no significant differences in latency to enter a dark room in the absence of a foot shock in all groups (data not shown). However, latency to enter a dark compartment was markedly decreased 1 week after foot shock in Atrx ΔE2 mice by one-way ANOVA with Bonferroni's post-hoc test; n = 6 mice each. e, Representative immunoblot of P90 mouse brain lysates probed with the indicated antibodies (top panel). Densitometric analysis of Xlr3 normalized to β -tubulin (arbitrary units) (bottom panel). **P < 0.01 versus vehicle-treated WT mice, ##P < 0.01 versus vehicle-treated Atrx ΔE2 mice by one-way ANOVA with Bonferroni's post-hoc test; n = 4 mice each. f, The percentage of 5-methylcytosine as determined by bisulfite sequencing analysis in the medial prefrontal cortex and the hippocampus from male P90 WT or Atrx ΔE2 mice. **P < 0.01 by two-way ANOVA with Bonferroni's post-hoc test; n = 9 clones. (n = 3 mice; 3 clones were sequenced per mouse.) See also Supplementary Fig. 10e . g, The G-quadruplex prediction tool QGRS Mapper was used to identify potential G-quadruplex-forming sequences in the entire Xlr3b genomic DNA sequence, which is shown with exons highlighted in black and introns highlighted in gray (top panel). The QGRS Mapper provides a G score (plotted in blue), which indicates the likelihood of G-quadruplex formation. The image is adapted from the QGRS Mapper (http://bioinformatics.ramapo.edu/QGRS/index.php). Analysis of the indicated amplicons in chromatin from the hippocampus of P90 mice by ChIP with the indicated antibodies is shown (bottom panel). Results are expressed as the percent input. **P < 0.01, *P < 0.05 versus vehicle-treated WT mice, ##P < 0.01, #P < 0.05 versus vehicle-treated Atrx ΔE2 mice by one-way ANOVA with Bonferroni's post-hoc test; n = 6 mice each. For panels b-g, the means ± s.e.m are shown. Full-size scans of western blots are shown in Supplementary Fig. 13 . In panels a,c-f , the means ± s.e.m. are shown. Full-size scans of western blots are shown in Supplementary Fig. 13 .
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NATuRe MeDICINe relative to WT mice. 5-ALA or TMPyP4 administration also significantly rescued the reduced latency time (Fig. 5e and Supplementary  Fig. 11e ). In a Y-maze test, Atrx ΔE2 mice showed impairment based on the percentage of alternation behaviors relative to WT mice without a change in the total number of arm entries. 5-ALA or TMPyP4 administration significantly increased the percentage of spontaneous alternation behaviors in Atrx ΔE2 mice ( Fig. 5f and Supplementary Fig. 11f ). Many patients with ATR-X syndrome exhibit abnormal social behaviors, especially shyness and social withdrawal 46 . Interestingly, in interactions with WT mice, Atrx ΔE2 mice showed enhanced passivity, greater escape duration and decreased active social behaviors, such as following and sniffing. These changes were dramatically ameliorated in Atrx ΔE2 mice upon treatment with 5-ALA (Supplementary Fig. 11g ). Acute administration of a single 5-ALA dose (10 mg per kg, p.o.) did not ameliorate impaired learning and memory-related behaviors in Atrx ΔE2 mice (data not shown).
To confirm that TMPyP4 was present in the brain, we measured TMPyP4 fluorescence levels, as described in ref. 47 . Chronic intraperitoneal injection of TMPyP4 (twice weekly from P30 to P90) in mice increased fluorescence levels in some tissues, including the brain, suggesting that treatment allows intracerebral transferability and enables TMPyP4 accumulation in brain tissue ( Supplementary  Fig. 11h ). However, we stopped chronic TMPyP4 administration on day 60 owing to toxicity, as evidenced by reduced body weight ( Supplementary Fig. 11i ). Unlike the case with TMPyP4, 5-ALA pharmacokinetics and biodistribution, including in the brain, have been reported in humans 48 and rodents 49 . We confirmed that 5-ALA crosses the blood-brain barrier after oral administration. In the mouse brain, 5-ALA (3 mg per kg, p.o.) levels peaked at 30 min and then decreased to basal levels by 24 h after administration ( Supplementary Fig. 11j) .
To investigate the expression of other genes underlying these effects, we performed DNA microarray analysis of RNA extracted from the hippocampus of P90 WT, Atrx ΔE2 or 5-ALA-treated Atrx ΔE2 mice and focused on 31 genes differentially expressed (8 upregulated and 23 downregulated) in WT versus Atrx ΔE2 samples using a threshold of FDR < 0.05 and a log 2 fold change of > 0.5 or < − 0.5 (Supplementary Table 1 ). Rescued or not rescued genes were assessed using the difference between the average value in log 2 global normalization. 5-ALA treatment of Atrx ΔE2 mice significantly blocked differential expression of 71.0% of genes, including Xlr3b (Fig. 5g and Supplementary Table 3 ). Following analysis of mice treated with TMPyP4, we selected 138 genes differentially expressed (38 upregulated and 100 downregulated) in WT versus Atrx ΔE2 hippocampal samples using a threshold of log 2 fold change of > 1.0 or < − 1.0. TMPyP4 treatment of Atrx ΔE2 mice blocked differential expression of 92.8% of genes, including Xlr3b, leaving only 10 out of 138 genes differentially expressed (Supplementary Table 4 ).
Discussion
Here, we make several critical observations relevant to the activities of ATRX (Supplementary Fig. 12 ). Among genes altered in the Atrx ΔE2 mouse brain, the imprinted gene Xlr3b is significantly overexpressed. ATRX is enriched with DNMTs at G-quadruplexes in Xlr3b CGIs. We observed that reduced ATRX levels at a given site were accompanied by reduced DNMT levels and substantial DNA demethylation, suggesting that ATRX regulates DNA methylation by DNMT recruitment to G-quadruplexes.
Notably, forebrain-specific cKO of either DNMT1 or both DNMT1 and DNMT3A reportedly promotes increased Xlr3b expression in excitatory neurons 26, 27 . Moreover, recent genome-wide analysis revealed preferential ATRX localization at the DNA-methylated allele of many imprinted differentially methylated regions in mouse ESCs and that ATRX-bound CGI sequences were methylated to a greater extent than that seen in other parts of the genome 13 . ATRX deficiency also correlates with reduced H3.3 incorporation and with Pol II stalling at G-rich intragenic sites, indicating that ATRX influences Pol II-mediated transcription 16 . Accordingly, we detected Pol II accumulation at Xlr3b CGIs harboring G-quadruplexes in the WT hippocampus. We also found that cells in the Atrx ΔE2 hippocampus showed enriched Pol II signals across the Xlr3b gene relative to cells from the WT brain, and elevated Pol II signals in the Atrx ΔE2 hippocampus were significantly attenuated following 5-ALA treatment without changing DNA methylation levels. These results suggest that the porphyrin metabolites PpIX and hemin, which are derived from 5-ALA, bind to G-quadruplex structures, partially inhibiting Pol II recruitment, a mechanism supported by biophysical analysis of G-quadruplexes in the HIF1A, KRAS, CMYB and CMYC genes 41 . The G-quadruplex structure formed behind advancing Pol II may be recognized by other factors, including positive transcription elongation factor b 50 . In this context, further studies are required to define dynamic transcriptional structures interacting with the region bearing G-quadruplex motifs and how they regulate ATRXmediated DNA methylation and Pol II recruitment.
We also report a novel role for Xlr3b as a component of RNA granules containing RBPs, which inhibit Camk2a mRNA transport into neuronal dendrites. Xlr3b interacted with the dendritic mRNAs that encode CaMKII-α , Arc and BDNF via a 13-amino acid Cor1 domain, which binds to RBPs. This sequence is required for Camk2a mRNA transport, suggesting that RBP binding is also necessary for transport. Interestingly, that Xlr3b sequence is highly conserved in human FAM9 proteins, which also exhibit a Cor1 domain. Thus, binding ability may be common to proteins containing Cor1 domain motifs. In addition, our fluorescence imaging and electrophysiological analysis supports the idea that Xlr3b negatively regulates synaptic plasticity by inhibiting dendritic Camk2a mRNA transport in Atrx ΔE2 mice. Mice engineered to lack the 3′ UTR of Camk2a mRNA showed reduced levels of CaMKII-α transcripts at postsynaptic densities, reduced LTP and impaired spatial memory 38 . Dendritic transport and local translation of the mRNA encoding BDNF and Arc in synapses also enhance neuronal activity 33 , strongly suggesting that Xlr3b-mediated dendritic mRNA transport is related to learning and memory functions. 39X m O mice, a murine model of the female developmental disorder Turner syndrome, show aberrantly high Xlr3b expression in the brain, an outcome that is associated with difficulties in performing a reversal learning test, compared to 40XX and 39X p O mice 24 , suggesting that Xlr3b governs mouse behaviors. However, the mechanisms underlying these activities remain unknown. We also demonstrated that Thy1-Xlr3b TG mice show impaired LTP and memory deficits, indicating that aberrant neuronal Xlr3b expression partially affects dendritic mRNA transport and learning behaviors in Atrx ΔE2 mice. We also show that administration of the G-quadruplex ligands 5-ALA or TMPyP4 significantly rescues neuronal phenotypes seen in Atrx ΔE2 mice by inhibiting Xlr3b transcription. However, recovery of cognitive deficits in Atrx ΔE2 mice following 5-ALA administration may be due in part to the binding of ligand to G-quadruplexes of other ATRX targets, although this activity remains unknown. G-quadruplex motifs broadly influence transcription and translation 41 . In addition, ATRX can either repress or activate gene expression through G-quadruplexes 9, 51, 52 . Although potential off-target effects remain to be investigated, our findings suggest a novel therapeutic strategy aimed at blocking Xlr3b expression through smallmolecule binding to G-quadruplex DNA in patients with ATR-X Articles NATuRe MeDICINe syndrome. Among candidate ligands, 5-ALA has been applied clinically with minimal risk and approved for use following intracranial tumor resection in Europe, Canada and Japan
53
, where it has been used as a photosensitizer in photodynamic diagnostics applied in neurosurgery 54 . 5-ALA is also safe when administered chronically up to 200 mg per day in humans 55 . Thus, its approval time would be short and the cost of clinical trials would be reduced, as pre-existing absorption, distribution, metabolism, excretion (ADME) and toxicity data are available. Finally, the risk of failure is reduced as data relevant to 5-ALA safety and pharmacology are available.
In summary, our study indicates that G-quadruplex ligands regulate gene expression through a transcriptional mechanism involving Xlr3b and could be used to treat symptoms associated with ATR-X syndrome.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0018-6.
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NATuRe MeDICINe Methods Animals. Male mice (C57BL/6J) were used for all experiments. Mice were housed under climate-controlled conditions with a 12-h light/dark cycle and provided standard food and water ad libitum. Animal studies were conducted in accordance with the Tohoku University institutional guidelines. Ethical approval has been obtained from the Institutional Animal Care and Use Committee of the Tohoku University Environmental and Safety Committee. The generation of homozygous Atrx ΔE2 mice is described in ref. 19 . To generate Thy1-Xlr3b TG mice, Xlr3b cDNA was subcloned into the XhoI site of a mouse Thy1.2 expression cassette ( Supplementary Fig. 9a ). The Thy1 promoter construct was a gift of J. Sanes (plasmid 20736, Addgene). The Thy1.2-Xlr3b expression cassette was excised with NotI/PvuI and injected into fertilized eggs of B6 mice at Oriental Bio Service. Hemizygous Thy1-Xlr3b TG mice were generated by mating founder mice with B6 mice, and the offspring were screened by PCR using genomic tail DNA. Primers used for amplification of Xlr3b sequences were ThXl (FW) (5′ -GGTATTCATCATGTGCTCCG-3′ ) and ThXl (RV) (5′ -GTTTCTGCCTCTCTTCACAG-3′ ), and the detected PCR product was 479 base pairs in founder animals ( Supplementary Fig. 9b ).
Cell culture. Neuro-2a mouse neuroblastoma cells (CCL-131, American Type Culture Collection (ATCC), authenticated by the provider using short tandem repeat profiling) were grown in DMEM supplemented with 10% heat-inactivated FBS and penicillin/streptomycin (100 units per 100 μ g ml -1 ) in a 5% CO 2 incubator at 37 °C. Cells were routinely tested for mycoplasma contamination. Transfection was performed using Lipofectamine 2000 (Invitrogen) transfection reagent according to the manufacturer's protocol. Primary cultures of neurons were established using previously described methods with slight modifications 56 . Briefly, hippocampal tissue was dissected from embryonic day 18 mice and dissociated by trypsin treatment and trituration through a Pasteur pipette. Neurons were plated on coverslips coated with poly-l-lysine in MEM (Invitrogen) supplemented with 10% FBS, 0.6% glucose (Wako) and 1 mM pyruvate (Sigma-Aldrich). After cell attachment, coverslips were transferred to dishes containing a glial cell monolayer and maintained in Neurobasal Medium (Invitrogen) containing 2% B27 supplement (Invitrogen) and 1% GlutaMax (Invitrogen). Cytosine β -d-arabinofuranoside (5 μ m; Sigma-Aldrich) was added to cultures at 3 days in vitro (DIV3) after plating to inhibit glial proliferation. Primary neurons were transfected with expression vectors and shRNAs using electroporation (NEPA21; NEPAGENE) at DIV0.
Plasmid constructs and lentiviral transduction. Plasmids expressing cDNAs encoding Xlr3a, Xlr3b, FAM9A, DNMT1, DNMT3A, H3.3 and DAXX were obtained from Kazusa DNA Research Institute (Promega) and cDNAs were inserted into the pCMV vector. GST-Xlr3b was generated by cloning Xlr3b cDNA into pGEX-4T-1 (Pharmacia Biotech). The Atrx cDNA plasmid (pEGFP-C2-ATRX-HA) was kindly provided by D. Picketts (University of Ottawa, Canada). The ATRX shRNA (pSUPER-shATRX1) plasmid was kindly provided by N. Berube (University of Western Ontario, Canada). GFP-MS2-nls and MS2-binding site-CaMKII-α 3′ UTR constructs were kindly provided by K. S. Kosik (University of California Santa Barbara, Santa Barbara, CA, USA). Xlr3b shRNA was purchased from Sigma-Aldrich (MISSION TRC-Mm2.0 TRCN0000255204). The non-targeting hairpin control SHC002 (Sigma-Aldrich), which contains a sequence that does not target any known human or mouse gene, was used as a negative control (shControl). FLAG-Xlr3b (full length, Δ NLS, Δ 74-123, Δ 124-200 and Δ 158-170) and FLAG-FAM9A (full length and Δ 292-304) were generated using the KOD-Plus Mutagenesis Kit (Toyobo) according to the manufacturer's protocol. For construction of Xlr3b promoter plasmids, genomic DNA isolated from the mouse brain was obtained using a DNeasy Tissue Kit (Qiagen). PCR was carried out to amplify a fragment containing the Xlr3b promoter region from nucleotides − 2,085 to + 1 (where + 1 is the A of the translation initiation codon). The fragment was then subcloned into the pGL3-basic luciferase reporter (Promega) vector (pGL3-2K) and sequenced. pGL3-2KΔ G4 and pGL3-1KΔ CGI were generated using the KOD-Plus Mutagenesis Kit. The CRISPR-Cas9 and GFP fusion protein expression lentivirus, Xlr3-Cas9-GFP, was purchased from Sigma-Aldrich. The Xlr3 guide sequence was TCATCTTTCAGTGCCATGG. Lentiviral transduction was performed according to the manufacturer's protocol (Sigma-Aldrich).
Antibodies and peptides. The following primary antibodies were used; anti-Xlr3 (1:500, generated commercially (MBL)) against the TDTAGRHSRMDPNLSSDC peptide, anti-ATRX (1:100; H300 sc-15408, Santa Cruz Biotechnology), anti-DNMT1 (1:1,000, clone 60B1220.1; ab13537, Abcam), anti-DNMT3A Luciferase assay. Neuro-2a cells were co-transfected with pGL3 plasmids (pGL3-2K, pGL3-2KΔ G4 and pGL3-1KΔ CGI) plus a pRL-TK plasmid, which contains Renilla luciferase under the control of the herpes simplex virus thymidine kinase promoter, with or without other plasmids (ATRX, ATRX shRNA, control shRNA, DNMT1, DNMT3A, H3.3 or DAXX). For in vitro DNA methylation assays, pGL3 plasmids were incubated with 3U CpG methyltransferase (M.SssI) (New England Biolabs) for 4 h at 37 °C in the presence of 1 mM S-adenosyl methionine, following the manufacturer's instructions. Firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega) with a luminometer (Gene Light 55 Luminometer, Microtech). The ratio of Firefly to Renilla luciferase luminescence was calculated.
Identification of Xlr3 interaction proteins by mass spectrometry. Mouse brain tissues at P60 were lysed in buffer containing 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 0.1% Triton X-100, 4 mM EDTA, 4 mM EGTA, 1 mM Na 3 VO 4 , 50 mM NaF, 1 mM dithiothreitol and protease inhibitors (trypsin inhibitor, pepstatin A and leupeptin), followed by centrifugation at 15,000g for 10 min. Supernatants were collected and incubated with Protein A Sepharose column (Protein A HP SpinTrap, GE Healthcare Life Sciences) with TBS buffer (50 mM Tris-HCl, 0.15 M NaCl, pH 7.5) containing an Xlr3 antibody (10 μ g) at 4 °C for 4 h with constant rotation. Bound proteins were then washed with TBS and eluted with 2.5% acetic acid. To confirm specific binding, samples were run on SDS-PAGE and the gel was stained using a Silver Stain Kit (Wako). All samples were then analyzed by LC-MS/MS at Oncomics, as a custom service. Proteins identified in control samples that were pulled down with rabbit IgG (10 μ g) were subtracted from identified proteins.
Preparation of proteins binding to GST-Xlr3b. Preparation of proteins was performed using a GST Protein Interaction Pull-Down Kit (Pierce; Thermo Fisher Scientific) according to the manufacturer's instructions. GST and GST-Xlr3b were prepared in Escherichia coli BL21 and immobilized to glutathione affinity resin. Mouse hippocampal tissues were lysed in buffer containing 50 mM TrisHCl (pH 7.5), 0.15 M NaCl, 4 mM EDTA, 4 mM EGTA, 1 mM Na 3 VO 4 , 50 mM NaF, 1 mM dithiothreitol and protease inhibitors (trypsin inhibitor, pepstatin A and leupeptin), followed by centrifugation and incubation with immobilized glutathione affinity resin containing GST fusion proteins at 4 °C for 4 h with constant rotation. Bound proteins were then washed, eluted with glutathione elution buffer and run on SDS-PAGE.
Immunoprecipitation and immunoblotting.
Immunoprecipitation and immunoblotting analysis was performed as previously described 56 . Briefly, tissues or cells were homogenized in buffer containing 50 mM Tris-HCl (pH 7.5), 0.5% Triton X-100, 0.15 M NaCl, 4 mM EDTA, 4 mM EGTA, 1 mM Na 3 VO 4 , 50 mM NaF, 1 mM dithiothreitol and protease inhibitors (trypsin inhibitor, pepstatin A and leupeptin). For immunoprecipitation, lysates were incubated for 2 h at 4 °C with indicated antibodies with Protein A Sepharose CL-4B (GE Healthcare Life Sciences) in homogenization buffer. Subsequently, immunoprecipitates were washed three times with homogenization buffer, equivalent amounts of protein were electrophoresed on SDS-PAGE and proteins were then transferred to an Immobilon polyvinylidene difluoride membrane. After blocking with TTBS solution (50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.1% Tween 20) containing 5% fat-free milk powder for 1 h at room temperature, membranes were incubated overnight at 4 °C with indicated primary antibodies. After washing, membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody diluted in TTBS. Blots were developed using an ECL immunoblotting detection system (Amersham Biosciences). Immunoreactive bands were visualized using the luminescent image analyzer LAS-4000 (Fuji Film) and quantified using Image Gauge version 3.41 (Fuji Film).
Subcellular fractionation.
Primary hippocampal neurons at DIV21 were homogenized in ice-cold lysis buffer containing the following: 320 mM sucrose,
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NATuRe MeDICINe delivered from the floor. The mouse was removed from the apparatus 30 s later. After a 7-day interval, each mouse was placed in the light compartment and step-through latency was recorded over 300 s to assess retention. In the novel object recognition task, mice were individually habituated to an open-field box (35 × 25 × 35 cm 3 ) for 2 consecutive days. During the acquisition phase, two objects of the same material were placed symmetrically in the center of the chamber for 10 min. Twenty-four hours later, one object was replaced by a novel object and exploratory behavior was analyzed again for 5 min. After each session, objects were thoroughly cleaned with 70% ethanol to prevent odor recognition. Exploration of an object was defined as rearing on the object or sniffing it at a distance of < 1 cm, touching it with the nose or both. Successful recognition was reflected by preferential exploration of the novel object. Discrimination of spatial novelty was assessed by comparing the difference between exploratory contacts of novel and familiar objects and the total number of contacts with both, making it possible to adjust for differences in total exploration contacts. A social interaction test was established using methods described in ref. 57 with slight modifications. WT and Atrx ΔE2 mice were housed in new partitioned cages, such that the Atrx ΔE2 mouse occupied one compartment and a weight-matched WT mouse (non-littermate) occupied the other. Forty-eight hours later, the partition was removed and social interaction between mice was videotaped for 10 min. Scored behaviors were divided into four groups. Active social behavior, initiated by the experimental mouse towards the partner, includes: (1) sniffing of any part of the partner's body including the anogenital area; (2) following, including direct aggressive attacks accompanied by bites towards the partner's back. Passive social behavior, which occurs as a reaction to active behavior of the partner towards the experimental mouse, includes (3) receptive responses when the experimental mouse tolerates sniffing by the partner but shows no defensive or submissive behavior; (4) escape in response to a partner's following or aggressive act. Data were analyzed as the percentage of time spent in various social behaviors during a 10-min interaction test. The videotapes for all behavioral analysis were scored by a trained observer blind to the genotype and treatment.
Actin assays. An in vitro F-actin sedimentation assay was performed using the Actin Binding Protein Spin Down Assay (non-muscle) kit (BK013; Cytoskeleton). Briefly, recombinant Xlr3b protein (1 μ M) purified from E. coli or α -actinin were mixed with polymerized non-muscle actin (10 μ M) and incubated for 30 min at 22 °C. Mixtures were centrifuged to sediment F-actin, and supernatant and pellet fractions were analyzed by SDS-PAGE, followed by silver staining. Actin polymerization was measured using a pyrene-actin polymerization kit (BK003, Cytoskeleton) following the manufacturer's instructions.
CD spectra. All oligonucleotides were purchased from Sigma-Aldrich without further purification. Oligonucleotides for CD spectra were prepared in Li + solution or K + solution (20 mM lithium cacodylate (pH 7.0), 10 or 100 mM KCl). Annealing was performed by heating to 95 °C for 5 min and cooling down slowly to room temperature. CD spectra were measured in 0.5-nm steps from 340 to 220 nm using a JASCO J-805LST Spectrometer and 1-cm quartz cuvettes.
UV melting experiment. UV-visible melting temperature analyses were performed on a V-650 spectophotometer (JASCO) with a thermocontrolled PAC-743R cell changer (JASCO) and the refrigerated and heating circulator F25-ED (Julabo).
Oligonucleotides (ODN) (5 μ M) in K + solution (20 mM lithium cacodylate (pH 7.0), 5 mM KCl) and 1 eq compounds were added. Annealing was performed by heating to 95 °C for 5 min and slowly cooling to room temperature. The T m of each sample was measured at 295 nm from 15 to 95 °C at a rate of 1.0 °C per min. The Δ T m was calculated using T m values of samples with and without compounds.
Gel electrophoresis. DNA samples (ODN) for gel electrophoresis were prepared similarly to CD spectra samples. Annealing was performed by heating to 95 °C for 5 min and cooling slowly to room temperature. Each sample was analyzed by native gel (8%) in 1× TBE buffer containing 10 or 100 mM KCl at room temperature. Single-stranded DNA was stained with SYBR Green I Nucleic Acid Stain (50513, Lonza). Gels were then imaged by FLA-3000 (FUJIFILM). DMS footprinting. Samples (ODN) for DMS footprinting were prepared similarly to samples of CD spectra. DNA samples (10 μ l) were then mixed with 1 μ l DMS solution (DMS:ethanol; 4:1, v/v). Reactions were quenched with 9 μ l stop buffer (3 M β -mercaptoethanol:water:NaOAc; 1:6:7, v/v). After ethanol precipitation and piperidine cleavage, reactions were separated on 12% denaturing polyacrylamide gels using a Hitachi DNA sequencer. Electrophoresis was conducted under 1.5 kV, ~25 mA at 40 °C.
Statistical analysis.
To determine the sample size in our experiments, we followed the standard sample sizes used in similar experiments in each of the relevant fields in the literature. All values were expressed as means ± s.e.m. Comparisons between two experimental groups were made using the two-sided, unpaired Student's ttest. Statistical significance for differences among groups was tested by one-way or two-way analysis of variance (ANOVA) with post-hoc Bonferroni's multiple comparison test. P < 0.05 was considered significant. All the statistical analyses were performed using GraphPad Prism 7 (GraphPad Software). All statistical data are presented in Supplementary Table 5 .
Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability.
A summary of all statistical data is shown in Supplementary  Table 5 . Microarray raw data are available at Gene Expression Omnibus (GEO); accession numbers, GSE103031 (https://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc= GSE103031) and GSE103032 (https://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc= GSE103032). The other data that support the findings of this study are available from the corresponding authors on reasonable request. 
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